ERBB2 and cancer: There are multiple other examples in which DNA nanorobots can target HER2-positive breast cancer cells to induce apoptosis (Ma et al., 2019), deliver drug cargo to the cancer tissue mediated by nucleolin targeted therapy (Li et al., 2018), identification of cancer biomarkers (Mirzaiebadizi et al., 2022) and act as biosensors to allow the detection of target oligonucleotides and miRNAs (Domljanovic et al., 2022).